This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
New York-based Bristol-Myers Squibb is a one of the leading global specialty bio-pharmaceutical companies focused on the development of treatments targeting serious diseases. Backed by its blockbuster immune-oncology drug, Opdivo, Bristol-Myers has a strong oncology portfolio, consisting of other drugs like Revlimid, Sprycel, Yervoy and Empliciti. Beyond oncology, the company has important immunology and cardiovascular drugs like Orencia and Eliquis, which diversify its portfolio. Notably, in the cardiovascular space, Eliquis is now the global leading oral anti-coagulant drug. The company continues to experience growth in both the Eliquis brand and the market, while also advancing its Factor XIa inhibitor program..
Biotech Stock Roundup: BMY to Buy Forbius, BMRN Gets CRL & Other Updates
by Zacks Equity Research
The biotech sector remains in focus with drug approvals, and regulatory and other pipeline updates.
Signs That Your Trading Will Ruin Your Retirement - August 27, 2020
by Zacks Equity Research
Achieving your retirement goals takes a much different investing approach than regular stock trading, from smartly managing risk to keeping emotions in check.
Bristol Myers' Idhifa Fails to Meet Goal in Leukemia Study
by Zacks Equity Research
Bristol Myers' (BMY) phase III study evaluating Idhifa in patients with relapsed or refractory acute myeloid leukemia fails to meet the primary endpoint.
Bristol Myers to Buy Forbius to Boost Immunotherapy Pipeline
by Zacks Equity Research
Bristol Myers (BMY) enters into an agreement to acquire privately-held Forbius in a bid to boost its pipeline of immunotherapies.
Exelixis Files for Cabometyx Combo in First-Line Kidney Cancer
by Zacks Equity Research
Exelixis (EXEL) submits a supplemental new drug application to the FDA seeking approval of Cabometyx in combination with Opdivo for the treatment of advanced renal cell carcinoma.
Amgen's New Kyprolis Combo Gets FDA Nod for Multiple Myeloma
by Zacks Equity Research
Amgen's (AMGN) Kyprolis gets FDA approval for label expansion as second to fourth-line treatment for relapsed/refractory multiple myeloma in combination with J&J's Darzalex and dexamethasone.
Simple Secrets Anyone Can Use to Reach Early Retirement - August 21, 2020
by Zacks Equity Research
Accomplishing the financial cushion to retire early is a fantasy for most, but bringing that fantasy to reality is not as difficult as it sounds. If you are willing to make some serious lifestyle adjustments, it can be achievable.
The Extreme Risks of Trading Your Own Retirement Assets - August 19, 2020
by Zacks Equity Research
From understanding your risk tolerance to maintaining emotional control, achieving your retirement goals takes a much different investing approach than regular stock trading.
Biotech Stock Roundup: GILD Gets CRL, REGN Collaborates With RHHBY & More
by Zacks Equity Research
The biotech sector remains in focus with regulatory and other pipeline updates.
AstraZeneca's Imfinzi Gets Priority Tag for 4-Week Dosing
by Zacks Equity Research
The FDA grants priority review to AstraZeneca's (AZN) sBLA seeking approval of Imfinzi for a four-week fixed-dose regimen for its approved indications in bladder cancer and non-small cell lung cancer.
Bristol Myers & Dragonfly Team Up for Immunotherapy Program
by Zacks Equity Research
Bristol Myers (BMY) collaborates with Dragonfly Therapeutics, Inc. for its experimental immunotherapy program.
Easy Investing Secrets to an Early Retirement - August 13, 2020
by Zacks Equity Research
Achieving the financial freedom to retire early is a dream for most, but making that dream a reality isn't as tricky as it sounds. If you are willing to make some serious lifestyle changes and sacrifices, it can be possible.
Biotech Stock Roundup: BMY & REGN Q2 Earnings, Gilead NDA for Coronavirus Drug
by Zacks Equity Research
The biotech sector remains in focus with earnings, regulatory and other pipeline updates.
Halozyme (HALO) Q2 Earnings and Revenues Miss Estimates
by Zacks Equity Research
Halozyme (HALO) reports lower-than-expected Q2 earnings. Shares down.
Signs That Your Trading Will Ruin Your Retirement - August 11, 2020
by Zacks Equity Research
Achieving your retirement goals takes a much different investing approach than regular stock trading, from smartly managing risk to keeping emotions in check.
Biohaven (BHVN) Q2 Earnings Beat on Strong Nurtec Uptake
by Zacks Equity Research
Biohaven's (BHVN) recently approved migraine drug, Nurtec ODT, demonstrates strong launch uptake.
Pharma ETFs Soar on Robust Q2 Earnings
by Sweta Killa
Total earnings of 66.4% of the healthcare market capitalization that has reported so far are up 4.4% on revenue growth of 4%.
Clovis (CLVS) Q2 Earnings Lag, Revenues Show Coronavirus Impact
by Zacks Equity Research
Clovis (CLVS) reports dismal second-quarter 2020 results. Sales of the company's sole marketed drug, Rubraca, decline sequentially. Shares down.
Nektar's (NKTR) Q2 Earnings Beat, Bempeg Makes Progress
by Zacks Equity Research
Nektar (NKTR) reports encouraging second-quarter 2020 results. The company continues to progress with its pipeline candidates.
Acceleron (XLRN) Reports Narrower-Than-Expected Q2 Loss
by Zacks Equity Research
Acceleron (XLRN) posts a narrower-than-expected Q2 loss owing to increased revenues.
Exelixis' (EXEL) Q2 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Exelixis (EXEL) beats on earnings and sales in the second quarter.
Company News for Aug 7, 2020
by Zacks Equity Research
Companies In The News: BMY, CRON, BDX, LNG.
Should You Invest in the VanEck Vectors Pharmaceutical ETF (PPH)?
by Zacks Equity Research
Sector ETF report for PPH
Bristol Myers Squibb (BMY) Q2 Earnings and Revenues Top Estimates
by Zacks Equity Research
Bristol Myers (BMY) delivered earnings and revenue surprises of 11.64% and 0.44%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Bristol-Myers (BMY) Q2 Earnings Beat, 2020 Earnings View Up
by Zacks Equity Research
Bristol-Myers (BMY) beats on earnings and sales in the second quarter on the strength of Revlimid and Eliquis.